ASXL1 and myelodysplastic syndrome: While some of the molecular abnormalities associated with CH seem to be enriched in the PLWH who develop MDS compared with the HIV-negative counterparts (mainly ASXL1, DNMT3A and TP53 mutations, and higher risk cytogenetics) [26], progression of CH from >2% VAF and correlation with hematologic malignancy is not well defined [51].